GlobeNewswire

Bavarian Nordic Assists Public Health England in Response to New Cases of Monkeypox

Share

COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency (MHRA) to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox in the UK. Two related cases were confirmed and admitted to a hospital in Liverpool. One was most likely infected in Africa, where the family arrived from a few days before onset of disease, and a sibling case most likely infected on UK soil by the first case.

Monkeypox is a rare, but serious disease, which is endemic in Central and West Africa. The disease is quite similar to human smallpox, although it is less severe with an estimated fatality rate of 1-10%.

IMVANEX (MVA-BN) is approved by the European Commission for active immunization against smallpox but has also received approval for monkeypox by the U.S. Food and Drug Administration (FDA) and Health Canada, as the only vaccine approved for this indication in these territories. Bavarian Nordic previously delivered IMVANEX to PHE in connection with the first human cases of monkeypox in the UK in 2018 and later in 2019, when several unrelated human cases were imported from Nigeria with a subsequent infection of a healthcare worker in the UK.

Paul Chaplin, President and CEO of Bavarian Nordic said: “We are pleased to assist Public Health England rapidly in such an emergency situation. Vaccination is a critical measure to prevent and control the spread of diseases globally. Governments have an essential role in preparing for outbreaks by stockpiling vaccines and treatments so that they are readily available in events like this. We have a long history of working with other governments on strengthening their national preparedness in outbreak situations, and we urge more countries to actively consider and mitigate the risks of diseases like monkeypox, which unfortunately is on the rise in Africa and has in recent years shown to cross borders several times.”

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine based on an in-licensed capsid virus-like particle technology. The vaccine candidate, ABNCoV2, is currently being investigated in clinical trials. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Nexstim Abp: Styrelsens beslut gällande emission av aktier under bolagets villkorade aktieandelsprogram och riktad emission14.6.2021 14:30:00 CEST | Pressemelding

Företagsmeddelande,Helsingfors, 14.6.2021 kl. 15.30 (EEST) Nexstim Abp: Styrelsens beslut gällande emission av aktier under bolagets villkorade aktieandelsprogram och riktad emission Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) meddelar att med stöd av det bemyndigande som bolagets bolagsstämma gav i 11 maj, 2021 och det villkorade aktieandelsprogram som godkändes av årsstämman 26 mars 2016 har bolagets styrelse i dag beslutat att emittera sammanlagt 46 057 nya vederlagsfria aktier till styrelseledamöter. Leena Niemistö tilldelas 12 960 aktier, Martin Forss tilldelas 8 316 aktier, Rohan Hoare tilldelas 13 260 aktier och Tomas Holmberg tilldelas 11 521 aktier enligt sina respektive bruttoersättningar under intjänandeperioden 2020–2021, i enlighet med årsstämmobeslut av 30 april 2020. De nya aktierna registreras sannolikt kring 18 juni 2021. Efter emissionen kommer det totala antalet aktier i bolaget att vara 6 686 673. NEXSTIM ABP Styrelsen För mer information gå in på

Nexstim Plc: Decisions of the Board of Directors regarding issuance of shares under the restricted share unit plan and directed share issue14.6.2021 14:30:00 CEST | Press release

Company announcement, Helsinki, 14June2021 at 3:30 PM (EEST) Nexstim Plc: Decisions of the Board of Directors regarding issuance of shares under the restricted share unit plan and directed share issue Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that pursuant to the authorisation received from the Company's Annual General Meeting on May 11, 2021 and the restricted share unit reward plan approved by the Annual General Meeting on 26 March 2016, the Board of Directors of the Company has today resolved on issuing altogether 46 057 new shares without payment to members of the Board of Directors. Leena Niemistö will receive 12 960 shares, Martin Forss will receive 8 316 shares, Rohan Hoare will receive 13 260 shares and Tomas Holmberg will receive 11 521 shares based on the amount of the gross reward for the vesting period 2020-2021 determined by the Annual General Meeting on 30 April 2020. The new shares are expected to be listed on or about 18 June 2021. After the

Nokia Deepfield global analysis shows most DDoS attacks originate from fewer than 50 hosting companies14.6.2021 14:00:00 CEST | Press release

Press Release Nokia Deepfieldglobalanalysis shows most DDoS attacks originate from fewer than 50 hosting companies In-depth analysis across large sample of networks globally fingerprints and traces origins of most DDoS attacks (by frequency and traffic volume); finds that majority of DDoS attacks originate from fewer than 50 hosting companies and regional providers Nokia Deepfield shares strategies for fingerprinting and tracing primary DDoS sources; makes recommendations for addressing DDoS security with networking community Analysis shows more than 100% increase in daily DDoS peak traffic between January 2020 and May 2021 Identifies the threat potential for possible DDoS attacks over 10 Tbps – four to five times the scale of largest attacks reported so far (just above 2 Tbps) – due to rapidly growing number of open and insecure internet services and IoT devices Delivers Nokia Deepfield Defender, specifically designed to safely, securely and efficiently orchestrate DDoS mitigation acr

Ceylon Graphite Announces Licence for Vein Graphite and Graphene Technologies14.6.2021 13:15:00 CEST | Press release

VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Ceylon Graphite Corp. (“Ceylon Graphite”) (TSX-V: CYL) (OTC: CYLYF) (FSE: CCY) is pleased to announce that it has acquired an exclusive global licence from Cambridge Advanced Materials & Innovation (“CAMI”). The licence pertains to a method of producing high quality few-layer graphene (“FLG”) and derivatives by exfoliation of high grade vein graphite produced by Ceylon Graphite (“The Technology”). This is a low-energy process which results in high-yield, few layer graphene products. This industrial process is already fully designed for large volume production, and is scalable, with modules added as demand increases. Upon completion of the licence agreement, Ceylon Graphite has gained full access to all intellectual property surrounding The Technology and know-how. Use of Ceylon’s high-grade feedstock material- vein graphite - leads to minimal to nil industrial waste during the production of graphene. The combination of uniq

GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK14.6.2021 13:00:00 CEST | Press release

SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted a Promising Innovative Medicine (PIM) designation for voxelotor for the potential treatment of hemolytic anemia in adults and adolescent patients 12 years of age and older with sickle cell disease (SCD). Following a review by the MHRA, PIM designations are given to promising treatments that are likely to offer a major advantage for patients and are an early indication that the treatment is a promising candidate for the Early Access to Medicines Scheme (EAMS). For the MHRA to grant a PIM designation, the product must meet each of the following three criteria: The condition should be life-threatening or

Incap Corporation: INCAP CONTINUES TO RAMP UP ITS FACTORIES IN INDIA, LOCK-DOWN EXTENDED UNTIL 21 JUNE 2021. INCAP’S PREVIOUSLY ANNOUNCED OUTLOOK FOR 2021 REMAINS UNCHANGED.14.6.2021 10:45:00 CEST | Press release

Incap Corporation 14 June 2021 at 11:45 a.m. (EEST) Stock Exchange Release Insider information INCAPCONTINUES TO RAMP UP ITS FACTORIES IN INDIA, LOCK-DOWN EXTENDED UNTIL 21 JUNE 2021. INCAP’S PREVIOUSLY ANNOUNCED OUTLOOK FOR 2021 REMAINS UNCHANGED. Incap announced on 10 May 2021 that it had temporarily closed down its factories in Tumkur until 24 May 2021. On 24 May 2021, Incap announced that the lock-down had been extended until 7 June 2021 and that it had been granted a permission for partial operation of its factories. Currently, the lock-down in Karnataka has been extended until 21 June 2021. Incap’s factories in India continue to operate according to the government guidelines and Incap is prepared to resume full operations once the restrictions are removed. The closure and the partial operations of the factories in India do not have an impact on the company’s outlook for 2021 published on 21 April 2021. Incap’s previously announced outlook for 2021: Incap estimates that its revenu

2022 PAN EUROPEAN LAUNCH OF OKUMA REELS, RODS AND COMBOS BY RAPALA VMC CORPORATION SUPPORTED BY MASSIVE MARKETING CAMPAIGN14.6.2021 10:30:00 CEST | Press release

2022 PAN EUROPEAN LAUNCH OF OKUMA REELS, RODS AND COMBOS BY RAPALA VMC CORPORATION SUPPORTED BY MASSIVE MARKETING CAMPAIGN Rapala VMC Corporation (“Rapala VMC”) announced on January 27, 2021 the acquisition of Okuma European and Russian trademarks and associated intangible assets. Rapala VMC is now pleased to announce that the largescale launch of Okuma reels, rods and combos in Europe and Russia will occur January 1, 2022. Svendsen Sport A/S (“Svendsen“) and Okuma Fishing Tackle Co Ltd (“Okuma”) have recently agreed that Okuma’s long term exclusive distribution agreement with Svendsen covering Denmark, Norway, Sweden, Iceland, UK, Ireland, France, Germany, The Netherlands, Luxembourg, Austria, Belgium, Czech Republic, Hungary, Poland and Russia (“Svendsen Territory”) will terminate effective December 31, 2021 and that Svendsen’s rights to collect pre-orders terminates September 15, 2021. To facilitate a smooth transition, Rapala VMC has agreed to acquire Svendsen’s inventories of Okum